Why the study?
Does low-dose spironolactone reduce blood pressure in subjects with resistant hypertension?
Population
76 African American and white subjects with resistant hypertension on multidrug regimens including a…
Design
Cohort
Follow-up
6 months
Key result
Adding low-dose spironolactone to multidrug regimens in subjects with resistant hypertension reduced blood pressure by a mean of 25/12 mm Hg at 6 months, regardless of primary aldosteronism status.
Authors
Loading...
May support spironolactone addition in resistant hypertension; leaves open randomized confirmation irrespective of aldosteronism.
Observational (n=76)
Does low-dose spironolactone reduce blood pressure in subjects with resistant hypertension?
Low-dose spironolactone provides significant additive blood pressure reduction in patients with resistant hypertension, regardless of the presence of primary aldosteronism.
Mari Nishizaka (2003) conducted an observational in Resistant hypertension (n=76). Spironolactone was evaluated on Decrease in blood pressure. Adding low-dose spironolactone to multidrug regimens in subjects with resistant hypertension reduced blood pressure by a mean of 25/12 mm Hg at 6 months, regardless of primary aldosteronism status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: